Compare Gilead Sciences, Inc. (GILD) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs IAC/Interactivecorp — how do they compare? Gilead Sciences, Inc. trades at $135.61 (market cap $163.51B), while IAC/Interactivecorp trades at $45.95 (market cap $3.41B). The key difference: Gilead Sciences, Inc. is far larger — about 48× IAC/Interactivecorp's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.
| GILD | PPLI | |
|---|---|---|
Market Cap | $163.51B | $3.41B |
Sector | Health | Media |
52-Week High | $155.80 | $47.62 |
52-Week Low | $108.22 | $31.52 |
Enterprise Value | $178.05B | $3.71B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PPLI trades at $45.80, up 1.1% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $5.2B in 2022 to $2.4B in 2025 and negative earnings in recent quarters, though 2026 projects a return to profitability. Analyst consensus is strongly bullish with a $55.40 price target, supported by potential acquisition interest from MGM Resorts. Cash flow volatility remains a concern with a significant net outflow of $820M in 2025.
The stock presents speculative upside based on acquisition potential and analyst optimism, but faces substantial execution risks amid declining revenue and negative earnings. Investors should weigh the strong institutional support against fundamental weaknesses and cash flow challenges when considering position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
